Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

The owners of Biogen stock will examine Biogen earnings to asss the progress that BIIB is making in key areas, including Ms and Spinraza. 
The post MS Franchise, Spinraza Likely to Be Key Catalysts for Biogen Stock appeared first on InvestorPlace.

MS Franchise, Spinraza Likely to Be Key Catalysts for Biogen Stock

Investors will key into Biogen earnings before the market opens Tuesday to better understand the biotech company's ongoing efforts in Alzheimer's treatment, according to an analyst.
The post Biogen Earnings: Here's What Investors Are Hoping To See In Report appeared first on Investor's Business Daily.

Biogen Earnings: Here's What Investors Are Hoping To See In Report

Evercore

Diamondback Energy

Knight-Swift Transportation Holdings

Toll Brothers

For sustained growth in profits, a company needs growth in the top line--revenue.

Biogen And Four Other Stock Buys With Rapid Revenue Growth

While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

Alexion Pharma

Amgen

Celgene

Gilead Sciences

MannKind

The short interest data are out for the most recent settlement date, June 28. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Short Sellers Run for Cover From Major Biotechs

BorgWarner

ConocoPhillips

Hibbett Sports

MarineMax

MetLife

Miller Industries

Reliance Steel & Aluminum

Taubman Centers

Perhaps the phrase “Perfect 10” makes you think of a perfect score in gymnastics.

Have a Gander at My Perfect 10 Portfolio

AbbVie

Allergan

Bristol-Myers

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

Will Patent Woes Boost Pharma Stock Megamergers Further?

Eli Lilly

Pfizer

Regeneron Pharmaceuticals

While the public wants more pharmaceuticals and biotech advancements to treat the endless number of ailments or to extend their lives, there is a simultaneous push to make drugs more affordable.

Many Top Pharma & Biotechs Rise As Drug Price Disclosure Thrown Out

Biogen's swing and miss in Alzheimer's disease has weighed on its shares this year.

Why Biogen Stock Has Plummeted in 2019

Johnson & Johnson

Vertex Pharmaceuticals

Large biotech companies Gilead Sciences and Vertex Pharmaceuticals are poised to beat Wall Street's second-quarter revenue expectations, according to investment bank RBC Capital Markets.

Why These 4 Biotech Leaders Could Rebound On Strong Earnings

HCA Healthcare

Health care stocks took a hit last week after President Donald Trump signed an executive order calling for more transparency in disclosing hospital costs to patients.

2 Health Care Companies to Consider for the 2nd Half of the Year

Mirati Therapeutics

These three biotech stocks should be outstanding long-term growth vehicles.

Three Top Biotech Stocks to Buy Right Now

Novo Nordisk

Roche Holding AG

Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.

The 10 Biggest Biotech Stocks

Biogen (BIIB) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook Biogen (BIIB)

If you’re looking for the next big thing in investing, these three down but not out biotech stocks are the way to go.

3 Large-Cap Biotech Stocks to Buy for Massive Gains

Pfizer could be only the first of several to spend billions buying smaller biotech.

3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal

Baidu

Bank of New York Mellon

FedEx

Vodafone Group

Walgreens

While gurus hold positions in these companies, the share prices and returns continue to fall.

6 Guru Stocks With Negative Returns

AstraZeneca

Biohaven Pharmaceutical Hld

Merck

Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.

Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures

Biogen (BIIB) closed the most recent trading day at $230.86, moving +0.19% from the previous trading session.

Biogen (BIIB) Gains But Lags Market: What You Should Know

Key insiders have been buying the stock for a reason. They're a bargain. Critically, they constitute, not mere value, but also a bet on growth investment status recapture.

BIIB Is For Buy-O-Gen

Athersys

Hypoxia is a core problem in stroke and other ischemic injuries.

Time Is Brain: Bioxytran's Tissue Oxygenation Therapy May Breathe New Life Into Stroke Victims

Biogen (BIIB) closed the most recent trading day at $227.33, moving +1.33% from the previous trading session.

Biogen (BIIB) Outpaces Stock Market Gains: What You Should Know

Novartis

Teva Pharmaceutical

The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

Celgene's Filing for Ozanimod Accepted for Review in US/EU

News for Biogen Stock (BIIB)